-
2023-506327-29-00
5
2025-05-14
Non-Small Cell Lung Cancer
-
2023-508773-82-00
5
2025-05-06
Stage IIB-IIIB (N2) resectable non small cell lung cancer
-
2024-511435-10-00
1
2025-04-30
Hepatocellular Carcinoma
-
2024-510893-25-00
5
2025-04-29
Brain metastases of cancer > brain radionecrosis
-
2024-519162-46-00
1
2025-04-25
Advanced Solid Tumors
-
2024-514465-18-00
9
2025-04-23
Advanced or Metastatic Non-Squamous NSCLC
-
2024-512043-22-00
4
2025-04-11
Metastatic prostate cancer
-
2024-512058-11-00
1
2025-04-09
Advanced Solid Tumor
-
2023-504180-16-00
5
2025-04-07
Advanced Breast Cancer
-
2023-508507-20-00
5
2025-04-03
Locally advanced or metastatic conventional chondrosarcoma with an IDH
-
2022-501489-24-00
5
2025-03-28
First-line treatment of adult subjects with high-risk large B-cell lym
-
2024-512729-10-00
4
2025-03-27
Recurrent or metastatic solid cancer harboring a FGFR1,2 ,3 fusion/rea
-
2023-507937-14-00
7
2025-03-25
Metastatic Solid Tumor
-
2024-513285-19-00
1
2025-03-14
Pancreatic Ductal Adeno Carcinoma
-
2024-513443-93-00
4
2025-03-10
Recurrent Meningioma without local treatment options (Surgery or Radio
-
2022-501315-13-00
5
2025-03-06
Patients with lateralised oropharyngeal, laryngeal and hypopharyngeal
-
2023-505291-30-01
4
2025-03-06
Triple Negative Breast Cancer with residual disease after neoadjuvant
-
2023-507873-16-00
11
2025-03-04
1st line treatment for unresectable metastatic colorectal cancer
-
2024-513687-26-00
1
2025-02-25
Advanced Solid Tumors
-
2024-516049-38-00
4
2025-02-18
CML-CP or CML-AP patients with T315I mutation
-
2023-509787-15-00
5
2025-02-17
Patients with localised prostate cancer and high-risk features of rela
-
2024-511159-16-00
6
2025-02-14
digital osteoarthritis
-
2024-514281-39-00
5
2025-02-14
Metastatic Squamous Non-small Cell Lung Cancer Whose Tumors Express PD
-
2024-515008-38-00
5
2025-02-14
Metastatic Non-squamous Non-small Cell Lung Cancer Whose Tumors Expres